CN104784297B - One kind resists allergic composition - Google Patents
One kind resists allergic composition Download PDFInfo
- Publication number
- CN104784297B CN104784297B CN201410024843.5A CN201410024843A CN104784297B CN 104784297 B CN104784297 B CN 104784297B CN 201410024843 A CN201410024843 A CN 201410024843A CN 104784297 B CN104784297 B CN 104784297B
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- composition
- dry product
- calculated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000000172 allergic effect Effects 0.000 title claims abstract description 9
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 99
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 22
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 21
- 229940105902 mint extract Drugs 0.000 claims abstract description 19
- 229940064064 purslane extract Drugs 0.000 claims abstract description 19
- 240000001745 Rheum palmatum Species 0.000 claims abstract description 18
- 241000246044 Sophora flavescens Species 0.000 claims abstract description 18
- 241000594394 Hedyotis Species 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
- 230000001139 anti-pruritic effect Effects 0.000 claims abstract description 4
- 239000003908 antipruritic agent Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 229930003944 flavone Natural products 0.000 claims description 18
- 235000011949 flavones Nutrition 0.000 claims description 18
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 17
- 150000002212 flavone derivatives Chemical class 0.000 claims description 17
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 13
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 238000001179 sorption measurement Methods 0.000 claims description 11
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 8
- 240000004064 Poterium sanguisorba Species 0.000 claims description 7
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims description 7
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims description 7
- 239000010282 Emodin Substances 0.000 claims description 6
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 5
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 5
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 5
- 229960000458 allantoin Drugs 0.000 claims description 5
- 229930014456 matrine Natural products 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 229940074391 gallic acid Drugs 0.000 claims description 4
- 235000004515 gallic acid Nutrition 0.000 claims description 4
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229930015582 oxymatrine Natural products 0.000 claims description 3
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 150000002213 flavones Chemical class 0.000 claims 1
- 102000001974 Hyaluronidases Human genes 0.000 abstract description 26
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract description 24
- 229960002773 hyaluronidase Drugs 0.000 abstract description 24
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000001151 other effect Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 239000006071 cream Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- 239000008351 acetate buffer Substances 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000030961 allergic reaction Diseases 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960001660 histamine phosphate Drugs 0.000 description 5
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 240000001659 Oldenlandia diffusa Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 240000004980 Rheum officinale Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000002052 anaphylactic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108050009363 Hyaluronidases Proteins 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 101001031591 Mus musculus Heart- and neural crest derivatives-expressed protein 2 Proteins 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 description 2
- 235000001855 Portulaca oleracea Nutrition 0.000 description 2
- 241000219304 Portulacaceae Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000002804 anti-anaphylactic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960001275 dimeticone Drugs 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229940085675 polyethylene glycol 800 Drugs 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000157511 Oldenlandia Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- KSZVHVUMUSIKTC-UHFFFAOYSA-N acetic acid;propan-2-one Chemical compound CC(C)=O.CC(O)=O KSZVHVUMUSIKTC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides one kind to resist allergic composition, and it is the external preparation being prepared with the raw material of following weight proportion：35 parts of purslane extract, 25 parts of herba hedyotis diffusae extract, 13 parts of shrubby sophora extract, 23 parts of mint extract, 13 parts of Radix Sangusorbae extract, 0.5 1 parts of Chinese rhubarb extract.Present invention also offers the purposes of said composition.The present composition, by each Chinese medicine reasonable compatibility, synergistic function is played, it is more good to the inhibitory activity of hyaluronidase, there is significant antiallergy, anti-inflammatory, antipruritic and other effects, there is provided a kind of new skin care item or medicine with antiallergy effect.
Description
Technical field
The present invention relates to one kind to resist allergic composition.
Background technology
In recent years, with the change of dietary structure, atmosphere pollution, the increase of live and work pressure, autopath is drastically
Increase.Especially in developed countries such as Japan, the U.S., skin sensitivity has become the social concern for influenceing human health.According to
Incomplete statistics, the crowd that the whole world feels sensitiveness skin is more and more, and wherein male accounts for 38%, and women accounts for 61%.Therefore
Cosmetics with antiallergic anti-irritant effect are increasingly subject to the attention of people, have the material of antiallergic anti-irritant activity, especially
Botanical components are favored by scholar and market.With modern experimental means research Chinese traditional herbs, it will help excavate high
Effect, low toxicity, the antiallergy product of low side effect.
Common cutaneous anaphylaxis is referred to as hypersensitivity, also known as allergy in medical science, refers to body by some anti-
During primary stimuli, there is the abnormal specific immune response based on physiological dysfunction or tissue cell insult.It takes
Certainly in two factors：The stimulation of antigen and the reactivity of body.Allergic constitution（irritable the physique）Usually
Allergic reaction and anaphylactia and the people that can not find pathogenic factor occurs by easy, is referred to as " allergic constitution ".Induced
The antigen of quick reaction is referred to as anaphylactogen.The antigenic substance to cause allergic reaction has hundreds of kinds, and they are by sucking, eating, injecting
Or the mode such as contact makes body sensitization.
According to traditional Chinese and western medicine and biology to allergic relevant explanation, with reference to the principle of the traditional Chinese medical science " integrated control ", make up
Product prevent and treat skin sensitivity and are with the common approach stimulated：1. away from anaphylactogen, sensibiligen autostimulation is reduced；2. suppress histamine
Etc. inflammatory mediator release；3. strengthen body barrier function；Above controlling way, the blocking of any one can all obtain certain anti-
Effect is controlled, but to reach good antiallergic effect, it should uses for reference and " overall preventing and treating " idea of the application traditional Chinese medical science, comprehensively and forms net
The preventing and treating of network shape, it can be only achieved excellent antiallergic effect.
The content of the invention
It is an object of the invention to provide a kind of composition with anti-allergic effects.Present invention also offers said composition
Purposes.
The invention provides one kind to resist allergic composition, it be prepared by the raw material of following weight proportion it is outer
Use preparation：
Purslane extract 3-5 parts, herba hedyotis diffusae extract 2-5 parts, shrubby sophora extract 1-3 parts, mint extract 2-3
Part, Radix Sangusorbae extract 1-3 parts, Chinese rhubarb extract 0.5-1 parts.
Further, it is the external preparation being prepared by the raw material of following weight proportion：
5 parts of purslane extract, 4 parts of herba hedyotis diffusae extract, 2 parts of shrubby sophora extract, 2 parts of mint extract, garden burnet
2 parts of extract, 1 part of Chinese rhubarb extract.
Wherein, in the purslane extract, calculated by dry product, general flavone content is no less than 15%w/w；Oldenlandia
In careless extract, calculated by dry product, general flavone content is no less than 1.0%w/w；In shrubby sophora extract, calculated by dry product, it is bitter
The total content of ginseng alkali and oxymatrine is no less than 1.2%w/w；In mint extract, calculated by dry product, general flavone content is not
Less than 2.0%w/w；In Radix Sangusorbae extract, gallic acid content is no less than 4.0%w/w；In Chinese rhubarb extract, calculated by dry product,
The total content of rheum emodin and Chrysophanol is no less than 0.45%w/w.
Further, in the purslane extract, calculated by dry product, general flavone content 18-25%w/w；Long-noded pit viper
In diffusa extract, calculated by dry product, general flavone content 3-7%w/w；In shrubby sophora extract, calculated by dry product, kuh-seng
The total content of alkali and oxymatrine is 2-4%w/w；In mint extract, calculated by dry product, general flavone content 3-5%w/
w；In Radix Sangusorbae extract, gallic acid content 4-5%w/w；In Chinese rhubarb extract, calculated by dry product, rheum emodin and Chrysophanol
Total content be 10-12%w/w.
Wherein, the preparation method of each extract is as follows：Corresponding medicinal material is taken, it is non-on water extract respectively after extracting in water
Polarity or intermediate-polarity macroporous adsorption resin post, after ion, then with 70~80%v/v ethanol elutions, ethanol eluate is collected,
Reclaim ethanol after, dry, i.e., respectively each extract.
In view of in ethanol eluate configuration process, ethanol raw material mass discrepancy, the volatilization loss of ethanol situations such as, may
The deviation of caused concentration of alcohol, the concentration of elution ethanol can receive certain error range in the present invention, such as using
65~85%v/v ethanol is eluted.
The nonpolar or intermediate-polarity macroporous adsorption resin post used in the present invention can select commercially available conventional model, such as
Nonpolar macroporous adsorption resin has HPD-100, HPD-300, D-101, X-5 or H103 etc., and intermediate-polarity macroporous adsorption resin has AB-
8, DA-201, HPD-400 or DM301 etc..Above-mentioned model is only for example, specific make to workable macroreticular resin type
Used time can be not limited to above-mentioned model.Consider for materials'use frequency and cost etc., the specific embodiment of the invention
The middle nonpolar macroporous adsorption resin used is D101, intermediate-polarity macroporous adsorption resin DM301.
Wherein, the composition be using each extract as active component, it is auxiliary plus what is commonly used in pharmaceutically or cosmetically
The preparation for external application to skin that material or complementary composition are prepared.
Wherein, the complementary composition is collagen, vitamin, co-ferment Q10 or/and allantoin.
Wherein, the external preparation is face cream, emulsion, gel, toner or facial mask.
Present invention also offers purposes of the above-mentioned composition in Hyaluronidase inhibitor is prepared.
Present invention also offers above-mentioned composition to prepare antiallergy, antipruritic or/and anti-inflammatory external use skin care or medicine
In purposes.
The present composition, by each Chinese medicinal material extract reasonable compatibility, synergistic function is played, to hyaluronidase
Inhibitory activity it is more good, there is significant antiallergy, anti-inflammatory, antipruritic and other effects, there is provided one kind has antiallergy effect
New skin care item or medicine.
Embodiment
The preparation method of 1 each medicinal substances extract of embodiment
The preparation method of extract is as follows：Weigh each raw material of purslane, oldenlandia diffusa, kuh-seng, peppermint, garden burnet, rheum officinale
Medicine, crush as coarse powder, add water to cook respectively three times, 1.5 hours every time；By the decocting liquid of each bulk drug, D101 macropores are crossed respectively
Resin adsorption, is eluted with water colourless to water lotion, with 70%v/v ethanol elutions to colourless, collects 70% ethanol eluate filtrate, filter
Ethanol is recovered under reduced pressure in liquid, concentrate eluant, concentrate spray drying, produces.
With each extract of high effective liquid chromatography for measuring：In purslane extract, weight percentage containing general flavone is
24.80%；In herba hedyotis diffusae extract, weight percentage containing general flavone is 6.25%；In shrubby sophora extract, the alkali containing ginseng and oxygen
The weight percentage for changing matrine is 3.7%；In mint extract, general flavone content 3.2%；In Radix Sangusorbae extract, do not eat
The sour weight percentage of son is 5.5%；In Chinese rhubarb extract, the total amount containing rheum emodin and Chrysophanol is 10.06%.
The preparation method of 2 each medicinal substances extract of embodiment
The preparation method of extract is as follows：Weigh each raw material of purslane, oldenlandia diffusa, kuh-seng, peppermint, garden burnet, rheum officinale
Medicine, crush as coarse powder, add water to cook respectively three times, 1.5 hours every time；By the decocting liquid of each bulk drug, DM301 macropores are crossed respectively
Resin adsorption, is eluted with water colourless to water lotion, with 80%v/v ethanol elutions to colourless, collects 80% ethanol eluate filtrate, filter
Ethanol is recovered under reduced pressure in liquid, concentrate eluant, concentrate spray drying, produces.
With each extract of high effective liquid chromatography for measuring：In purslane extract, weight percentage containing general flavone is
18.56%；In herba hedyotis diffusae extract, weight percentage containing general flavone is 3.85%；In shrubby sophora extract, the alkali containing ginseng and oxygen
The weight percentage for changing matrine is 2.4%；In mint extract, general flavone content 4.8%；In Radix Sangusorbae extract, do not eat
The sour weight percentage of son is 4.1%；In Chinese rhubarb extract, the total amount 11.36% containing rheum emodin and Chrysophanol.
The preparation of 3 face cream of the present invention of embodiment
A oil phases（Percentage by weight）
Beeswax 3.5%, stearic acid 3.2%, glycerin monostearate 1%, hexadecanol 3.0%, white oil 0.5%, dimeticone
0.5%th, vitamin D 0.6%, vitamin E 0.8%；
B aqueous phases（Percentage by weight）
Purslane extract 5%, herba hedyotis diffusae extract 4%, shrubby sophora extract 2%, mint extract 2%, garden burnet extraction
Thing 2%, Chinese rhubarb extract 1%, polyethylene glycol 400 6.5%, carboxyethyl cellulose 0.31%, allantoin 0.5%, vitamin C 0.5%, go
Ionized water complements to 100%；
Preparation method：After aqueous phase and oil phase are heated into fusing respectively, while aqueous phase stirs, it is slowly added into oil phase and stirs
Mix, continue to stir 1h, stop stirring, stand, be cooled to room temperature, produce antiallergy face cream.Each extract comes from the present embodiment
Embodiment 1.
The preparation of 4 emulsion of the present invention of embodiment
A oil phases（Percentage by weight）
Poloxamer 3%, span601.5%, polysorbate60 2%, dimeticone 18%, tragcanth 0.5%, tristerin
5%th, bone collagen 1%, vitamin E 0.8%；
B aqueous phases（Percentage by weight）
Purslane extract 4%, herba hedyotis diffusae extract 3%, shrubby sophora extract 3%, mint extract 2%, garden burnet extraction
Thing 2%, Chinese rhubarb extract 1%, glycerin extract 7%, carbomer 3.5%, ethyl hydroxy benzoate 2%, polypropylene glycol 0.5%, vitamin
B0.5%, vitamin C 0.5%, deionized water complement to 100%；
Preparation method：It is uniformly mixed after oil phase and aqueous phase are respectively melted, slowly will be mixed while oil phase stirs
Aqueous phase after conjunction, which is added in emulsion tank, to be stirred, and is continuously stirred 20min, is stopped stirring, stands cooling room temperature, produces antiallergy breast
Liquid.Each extract comes from embodiment 1 in the present embodiment.
The preparation of the inventive gel of embodiment 5
Raw material is weighed as following weight percent：Purslane extract 4%, herba hedyotis diffusae extract 4%, shrubby sophora extract
2%th, mint extract 2%, Radix Sangusorbae extract 2%, Chinese rhubarb extract 0.5%, Acritamer 940 1.5%, glycerine 5.5%, triethanolamine
0.1%th, ethyl hydroxy benzoate 0.1%, polyoxyethylene sorbitan monoleate 0.2%, distilled water complement to 100%；
Preparation method：Carbomer and polysorbate are dissolved in 30ml distilled water, triethanolamine solution is added, after stirring evenly
Add purslane extract, herba hedyotis diffusae extract, shrubby sophora extract, mint extract, Radix Sangusorbae extract, rheum officinale extraction
Thing, then ethyl hydroxy benzoate is gradually added into and stirred evenly, produce antiallergy gel.Each extract comes from embodiment 1 in the present embodiment.
The preparation of 6 toner of the present invention of embodiment
Raw material is weighed as following weight percent：Purslane extract 3%, herba hedyotis diffusae extract 5%, shrubby sophora extract
3%th, mint extract 3%, Radix Sangusorbae extract 1%, Chinese rhubarb extract 1%, glycerine 10%, butanediol 1.5%, polysorbate60 3%, tartaric acid 1%,
Citric acid 1%, hyaluronic acid 2%, carboxyethyl cellulose 2.5%, vitamin e1 %, deionized water complement to 100%；
Preparation method：Purslane extract, herba hedyotis diffusae extract, shrubby sophora extract, mint extract, garden burnet extraction
After thing, Chinese rhubarb extract mixing, glycerine, propane diols, tween, tartaric acid, bone collagen, co-ferment Q10, polyethylene glycol are added
400, vitamin E, deionized water complement to that 100ml is well mixed to produce antiallergy toner.Each extract comes in the present embodiment
From embodiment 1.
The preparation of 7 facial mask of the present invention of embodiment
Raw material is weighed as following weight percent：Purslane extract 5%, herba hedyotis diffusae extract 2%, shrubby sophora extract
1%th, mint extract 2%, Radix Sangusorbae extract 3%, Chinese rhubarb extract 0.5%, glycerine 15%, polyethylene glycol-800 16%, trehalose 1%,
Allantoin 0.1%, EDETATE SODIUM 0.1%, co-ferment Q101%, vitamin e1 %, deionized water complement to 100%；
Preparation method：A small amount of deionized water is taken, polyethylene glycol-800, glycerine, trehalose heating stirring is added, is cooled to
Room temperature, allantoin, EDETATE SODIUM, hyaluronic acid, vitamin E are added, add purslane extract, oldenlandia diffusa extraction
Thing, shrubby sophora extract, mint extract, Radix Sangusorbae extract, Chinese rhubarb extract, are sufficiently stirred, and solid matter is divided in colloid
Dissipate uniformly, produce antiallergic mask.Each extract comes from embodiment 1 in the present embodiment.
Beneficial effects of the present invention are illustrated below by way of test example.
The present composition antiallergy of test example 1 is tested
（One）Hyaluronidase body outer suppressioning test
Hyaluronidase (HAase) is hyaluronic acid (HA) Specific lytic enzymes, and HA is in human development and regulation process
In occur and vascularization plays main inhibitory action such as cell adherence, orga- nogenesis, wound healing, tumour, suppress HAase's
Activity can make HA not be decomposed, and maintain normal physiological function.Hyaluronidase is external model experiment.Kakegawa etc. is reported
The various medicines for influenceing histamine release of mast cell can adjust the activity of hyaluronidase, and hyaluronidase activity suppresses and hypertrophy
Correlation (Kakegawa H, the Inhibitory effects of some having had between cells release histamine inhibitory activity
natural product on the activation of hyaluridse and their antiallergic
actions[J].Hen Pharm Bull,1991,40(6):1439~1422).Yoo etc. reports hyaluronidase participation group
Inflammatory process is knitted, is the participant of type i allergic reaction, reaction is participated in the anaphylactoid phase III causes de- of mast cell
Grain（Yoo,Effects of allergy-related drugs on hyaluridase action and histamine
by rat peritoneal mast cell[J].Tachan Sacngri Hakboechi.1988,22:59~72）.Therefore
Hyaluronidase body outer suppressioning test can evaluate the antianaphylaxis energy of sample as simple biochemical method.Due to hyalomitome
Sour enzyme external model is simple and easy, so this Bioexperiment method is widely adopted as an index of research anti-allergic effects
With.
Antiallergic activity detects:Elson-Morgan improved methods：
Hyaluronidase is the participant of type i allergic reaction, and research shows that hyaluronidase and inflammation, allergy have strong correlation
Property, the medicine that Kakegawa once reported various histamine release of mast cell can adjust the activity of hyaluronidase.
Preparation of reagents
(1) hyaluronidase：Solvent compound concentration 500u/mL hyaluronidases are done with hac buffer, be now with existing
With, it is impossible to overnight.
(2) potassium hyaluronate：Solvent compound concentration 0.5mg/mL potassium hyaluronates are done with hac buffer
(3)Buffer:Solution A (in the molten 1000mL distilled water of 0.2mol/L. acetic acid, i.e. 11.55mL glacial acetic acid) 4.8mL,
Solution B (0.2mol/L sodium acetate, i.e. 16.4 grams of CH3COONa or 27.2 gram of CH3COONa.3H2O is dissolved in 1000ml distilled water
In) 45.2mL, mixing, 100mL is diluted to, is made into the acetate buffer solution of pH=5.6.
(4) acetic acid acetone soln：50mL1.0mol/L sodium carbonate liquors and 3.5mL acetylacetone,2,4-pentanedione solution are well mixed.(face
With now matching somebody with somebody)
(5) preparation of P-DAB developers：0.8g paradime thylaminobenzaldehydes and 15mLHCl and absolute ethyl alcohol mixing are equal
Even use.
(6)CaCl2Solution：2.5moL/L.
(7) NaOH solution：5moL/L.
（8）Each determinand is configured to the solution for standby of 1.2mg/ml concentration, is grouped as follows：Each taste prepared by embodiment 1
Chinese medical extract, mixed according to the Chinese medical extract proportions of embodiment 3, be identified as 1 group of experiment；Embodiment 2 is prepared each
Taste Chinese medical extract, mixed according to the Chinese medical extract proportions of embodiment 3, be identified as 2 groups of experiment；Prepared by embodiment 1
Each taste Chinese medical extract, mixed respectively by each Chinese medical extract proportions in embodiment 4-7, be individually identified as testing 3-6 groups；
The medicinal extract preparation method of each single medicinal material extract is same as Example 1.
Experimental procedure：
By sample 0.5ml（A, B is managed）, distilled water 0.5ml（C, D is managed）Middle addition 0.5ml hyaluronidases（500U/ml）
（A, C is managed）With 0.5ml acetate buffer solutions pH=5.6（B, D is managed）20min is incubated in 37 DEG C；Add CaCl2Solution 0.1ml（A、B、
C, D is managed）20min is incubated in 37 DEG C；It is separately added into 0.5ml potassium hyaluronate liquid（A, C is managed）, 0.5ml acetate buffer solutions pH=5.6
（B, D is managed）Room temperature places 10min after being incubated 40min in 37 DEG C；It is separately added into 0.5ml distilled water（A, B, C, D are managed）,
0.1ml5mol/L NaOH solutions（A, B, C, D are managed）With 0.5ml acetylacetone,2,4-pentanedione solution（A, B, C, D are managed）Ice after boiling water bath 15min
Water-bath 10min, room temperature 10min is placed, add 1ml P-DAB developers（A, B, C, D are managed）Add anhydrous second after each pipe fully shaking
Alcohol places room temperature 30min, absorbance is surveyed at 530nm to 8ml.
The calculating of antiallergic activity
Hyaluronic acid enzyme inhibition rate（%）=[（C-D）-(A-B)]/(C-D)×100%
In formula:A—（Hyaluronidase+sample+hyaluronidase potassium) sample solution OD values
The OD values of B-(acetate buffer solution+sample+acetate buffer solution) sample blank
The OD values of C-(hyaluronidase+deionized water+hyaluronidase potassium) contrast solution
D-(acetate buffer solution+deionized water+acetate buffer solution) compares the OD values of blank solution
As a result referring to table 1：
Influence of the table 1 to hyaluronidase
Hyaluronidase is the participant of type i allergic reaction, and research shows that hyaluronidase and inflammation, allergy have strong correlation
Property.From experimental result, the inhibiting rate of the present composition is higher than the inhibiting rate of single prescription element, shows that the present invention will be each
After taste medicinal material compound use, synergistic function has been played.As can be seen here, the present composition has significantly to hyaluronidase
Inhibitory action, it can be reached by the suppression to hyaluronidase and suppress anaphylactoid effect.
（Two）Influence to cavy local skin itch
Cavy 40, male and female half and half, 160~190g of body weight, random point four groups.1 group is blank control group；2 groups are the positive
Control group is cloudy with clean that；3 groups are test group 3（The face cream of embodiment 3）；4 groups are test group 4（The emulsion group of embodiment 4）.Before experiment
3, to instep shaving behind each group cavy right side, it is each that cloudy distilled water, clean that, the face cream of embodiment 3 and the emulsion of embodiment 4 were given respectively
0.5ml/ is only.The same day is tested, at instep shaving behind the coarse sandpaper scratch right side, 1 square centimeter of area is local to apply again 1 time, and last applies
10min after medicine, start in the histamine phosphate liquid 0.05ml/ of surface of a wound drop 0.01% only, hereafter every 3min according to 0.02%, 0.03%,
0.04% concentration incremented by successively, it is 0.05ml/ every time, until cavy occur later licks right metapedes, is returned with finally there is cavy
To lick the histamine phosphate total amount given during right metapedes be itch-threshold to head, and the cause for recording and comparing each group is itched domain.It the results are shown in Table 2.
Table 2 to histamine phosphate cause itch domain reaction influence
| Group | N | Itch thresholding（μg） |
| Blank control group | 10 | 63.13±28.14 |
| Clean cloudy group of that | 10 | 185.60±64.02** |
| Test group 3 | 10 | 178.07±84.20** |
| Test group 4 | 10 | 165.38±53.56** |
Note：Compared with physiological saline group, * P ＜ 0.05, * * P ＜ 0.01
Anaphylactoid to normally behave as pruitus, from experimental result, the present composition has significant stop
Itch effect, it is inhibited to itch caused by allergic reaction.
（Three）Influence to auricle edema caused by mouse dimethylbenzene
Healthy male mice 40,20~22g of body weight is taken, is randomly divided into four groups, every group 10.Blank control group distillation
Water 0.5ml/ only, is applied 1 time for 1 day.Positive controls apply fluocinonide ointment and applied 1 time for 1 day, and above each group applies 0.5g/ only every time；
Test group 3 is that the face cream group of embodiment 3 applies face cream 1 day 1 time, and 0.5g/ is only；Test group 4 is that the emulsion group of embodiment 4 applies emulsion group
1 day 1 time, 0.5g/ is only.Administrated method:Tested material or distilled water are coated in mouse right ear exterior feature, even applied 3 days.1 is small after last coating
When, by the Evans blue physiological saline 0.1ml/10g of mouse tail vein injection 0.5%, then auricle melted paraxylene 0.03ml makes to the right
Do not have and auricle inside and outside.Mouse is taken off into cervical vertebra after 40min to put to death.Left and right auricle diameter 8mm card punch is cut respectively two
Ear lays round auricle with position.Weigh weight in the balance, the difference of left and right auricle weight is swelling, seeks swelling inhibiting rate.Then by ear
Piece shreds, and is put into 7：Soaked 48 hours in 3 acetone physiological saline, 15min is centrifuged with 300rpm, takes supernatant in 600nm wavelength
Colorimetric.OD value is recorded, the results are shown in Table 3.
Influence of the table 3 to auricle edema caused by mouse dimethylbenzene
| Group | n | Swelling inhibiting rate | OD value |
| Blank control group | 10 | -- | 0.068±0.021 |
| Positive controls | 10 | 60.4 | 0.023±0.013** |
| Test group 3 | 10 | 49.6 | 0.031±0.015* |
| Test group 4 | 10 | 56.3 | 0.032±0.015* |
Note：Compared with physiological saline group, * P ＜ 0.05, * * P ＜ 0.01
Test result indicates that:Positive group, test group and blank control group relatively have significant difference, illustrate that tested material has suppression
The effect of auricle edema caused by dimethylbenzene processed, show that the present composition has antiinflammatory action, pass through the inhibitory action to inflammation
Reach antianaphylactic effect.
（Four）Influence to capillary permeability caused by rat intracutaneous injection histamine phosphate
Rat 40,180~220g of body weight, male and female half and half, random point four groups.Remove belly wool, area 4 with electric hair cutter
× 5cm, to apply tested material area at unhairing.Blank control group only, is applied 1 time for 1 day with distilled water 0.5ml/.Positive controls apply acetic acid
Fluocinolone acetonide ointment applies 1 time for 1 day, and above each group applies 0.5g/ only every time;The face cream group of embodiment 3 applies face cream 1 day 1 time, 0.5g/
Only（Test group 3）；The emulsion group of embodiment 4 applies emulsion group 1 day 1 time, and 0.5g/ is only（Test group 4）.It is continuous to apply 7 days, after last coating
30 minutes, by 0.1% Evans blue physiological saline 0.5ml/100g intravenous, animal is put to death after 30min, bloodletting, peels off skin chi
Son measurement stained area, then shreds and is put into 7：3 acetone physiological saline soak 48 hours, centrifuge 15min with 300rpm, take supernatant
Liquid is in 600nm wavelength colorimetrics.Record OD value.It the results are shown in Table 4.
Influence of the table 4 to capillary permeability caused by rat intracutaneous injection histamine
| Group | n | Stained area | OD value |
| Blank control group | 10 | 68.13±12.37 | 0.239±0.074 |
| Positive group | 10 | 30.13±9.58** | 0.113±0.052** |
| Test group 3 | 10 | 36.76±11.84* | 0.130±0.039* |
| Test group 4 | 10 | 38.59±10.16* | 0.124±0.046* |
Note：Compared with physiological saline group, * P ＜ 0.05, * * P ＜ 0.01
The capillary permeability caused by rat intracutaneous injection histamine phosphate is increased by composition it can be seen from result of the test
Added with inhibitory action, illustrate that the present composition has antiinflammatory action, by reaching antianaphylactic effect to the inhibitory action of inflammation.
Claims (11)
1. one kind resists allergic composition, it is characterised in that：It is the external application being prepared by the raw material of following weight proportion
Preparation：
Purslane extract 3-5 parts, herba hedyotis diffusae extract 2-5 parts, shrubby sophora extract 1-3 parts, mint extract 2-3 parts,
Radix Sangusorbae extract 1-3 parts, Chinese rhubarb extract 0.5-1 parts；
In the purslane extract, calculated by dry product, general flavone content is no less than 15%w/w；Herba hedyotis diffusae extract
In, calculated by dry product, general flavone content is no less than 1.0%w/w；In shrubby sophora extract, calculated by dry product, matrine and oxygen
The total content for changing matrine is no less than 1.2%w/w；In mint extract, calculated by dry product, general flavone content is no less than 2.0%
w/w；In Radix Sangusorbae extract, gallic acid content is no less than 4.0%w/w；In Chinese rhubarb extract, calculated by dry product, rheum emodin and
The total content of Chrysophanol is no less than 0.45%w/w.
2. composition according to claim 1, it is characterised in that：It is prepared by the raw material of following weight proportion
External preparation：
5 parts of purslane extract, 4 parts of herba hedyotis diffusae extract, 2 parts of shrubby sophora extract, 2 parts of mint extract, garden burnet extraction
2 parts of thing, 1 part of Chinese rhubarb extract.
3. composition according to claim 1, it is characterised in that：In the purslane extract, calculated by dry product, always
Flavones content is 18-25%w/w；In herba hedyotis diffusae extract, calculated by dry product, general flavone content 3-7%w/w；Kuh-seng
In extract, calculated by dry product, the total content of matrine and oxymatrine is 2-4%w/w；In mint extract, by drying
Product calculate, general flavone content 3-5%w/w；In Radix Sangusorbae extract, gallic acid content 4-5%w/w；In Chinese rhubarb extract, press
Dry product calculates, and the total content of rheum emodin and Chrysophanol is 10-12%w/w.
4. according to the composition described in claim 1-3 any one, it is characterised in that：The preparation method of each extract is such as
Under：Take corresponding medicinal material, respectively after extracting in water, nonpolar on water extract or intermediate-polarity macroporous adsorption resin post, after ion,
Again with 65 ~ 85%v/v ethanol elutions, ethanol eluate is collected, after reclaiming ethanol, dries, produces active component.
5. composition according to claim 4, it is characterised in that：Described elution concentration of alcohol is 70 ~ 80%v/v.
6. composition according to claim 4, it is characterised in that：The nonpolar macroporous adsorption resin is D101；It is described
Intermediate-polarity macroporous adsorption resin is DM301.
7. according to the composition described in any one of claim 1,2,3,5,6, it is characterised in that：The composition is with described
Each extract is active component, the external preparation for skin being prepared plus the auxiliary material or complementary composition commonly used in pharmaceutically or cosmetically
Preparation.
8. composition according to claim 4, it is characterised in that：The composition be using each extract as activity into
Point, the preparation for external application to skin being prepared plus the auxiliary material or complementary composition commonly used in pharmaceutically or cosmetically.
9. composition according to claim 7, it is characterised in that：The complementary composition is collagen, vitamin, auxiliary
Ferment Q10 or/and allantoin.
10. purposes of the composition in Hyaluronidase inhibitor is prepared described in claim 1-8 any one.
11. composition described in claim 1-8 any one prepare antiallergy, antipruritic or/and anti-inflammatory external use skin care or
Purposes in medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410024843.5A CN104784297B (en) | 2014-01-20 | 2014-01-20 | One kind resists allergic composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410024843.5A CN104784297B (en) | 2014-01-20 | 2014-01-20 | One kind resists allergic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104784297A CN104784297A (en) | 2015-07-22 |
| CN104784297B true CN104784297B (en) | 2018-01-26 |
Family
ID=53549795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410024843.5A Active CN104784297B (en) | 2014-01-20 | 2014-01-20 | One kind resists allergic composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104784297B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105997648A (en) * | 2016-06-21 | 2016-10-12 | 江苏奇力康皮肤药业有限公司 | Skin protection gel containing natural extracts |
| CN106727112A (en) * | 2016-12-12 | 2017-05-31 | 广州环亚化妆品科技有限公司 | A kind of natural antiallergic composition and its preparation method and application |
| CN110538109A (en) * | 2019-09-18 | 2019-12-06 | 广东丸美生物技术股份有限公司 | Preservative, preparation method and application thereof, cosmetic and skin care product |
| CN112641849A (en) * | 2020-12-28 | 2021-04-13 | 成都市康飞药业有限公司 | Pharmaceutical or cosmetic composition for dry skin, and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110733A (en) * | 2013-02-06 | 2013-05-22 | 成都山信药业有限公司 | Skin-aging-resistant composition and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007126368A (en) * | 2005-11-01 | 2007-05-24 | Shiseido Co Ltd | Antiaging agent, collagenase inhibitor and antioxidant |
-
2014
- 2014-01-20 CN CN201410024843.5A patent/CN104784297B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110733A (en) * | 2013-02-06 | 2013-05-22 | 成都山信药业有限公司 | Skin-aging-resistant composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 愈参霜为主治疗婴儿湿疹158 例;伏爱;《四川中医》;20061231;第24卷(第7期);第96页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104784297A (en) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roy et al. | Current updates on Centella asiatica: phytochemistry, pharmacology and traditional uses | |
| CN104784297B (en) | One kind resists allergic composition | |
| CN104784296B (en) | One kind resists allergic composition and application thereof | |
| CN107375437A (en) | A kind of anti acne of traditional Chinese medicine composition and its application | |
| CN104208153B (en) | One kind treats dermopathic Chinese medicine composition and its preparation | |
| CN108514572A (en) | Chinese medicine composition, extract and preparation a kind of anti-inflammatory and that repair skin barrier | |
| CN108704021A (en) | The composition and preparation method impaired for skin allergy and skin barrier | |
| CN104027280B (en) | A kind of delay aging drug compositions and the application in cosmetics thereof | |
| CN106176784B (en) | It is a kind of for the pharmaceutical composition of dermatitis, application, preparation and preparation method thereof | |
| CN103202786B (en) | Traditional Chinese medicine composition extract with anti-dandruff function and application of same in cosmetic | |
| CN104784466B (en) | External medicine composition with Shu Min anti-irritant effects and preparation method thereof | |
| CN104173607B (en) | It is a kind of to treat pharmaceutical composition of chloasma and preparation method thereof | |
| CN105581974A (en) | External-use composition | |
| CN102335231B (en) | Chinese medicinal moisturizing cream for treating chloasma as well as preparation method and application thereof | |
| CN102048815B (en) | Traditional Chinese medicine composition and preparation with whitening and anti-speck efficacies, as well as preparation method thereof | |
| CN116603012A (en) | Traditional Chinese medicine gel and preparation method and application thereof | |
| CN102293847B (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| CN108567852A (en) | A kind of pharmaceutical composition of prevention diabetic neuropathy | |
| CN107412455A (en) | A kind of natural externally applied pharmaceutical composition for treating fash and preparation method thereof | |
| CN113274382A (en) | Application of tricin in preparation of external preparation for intervening skin photodamage | |
| CN107375613A (en) | A kind of Chinese medical extract and its external preparation that red blood trace on face effect is removed with Eradicates | |
| CN103751613B (en) | A kind of Chinese medicinal liniment treating wind heat blood-dryness type seborrheic dermatitis | |
| CN101904831B (en) | Application of alkannin and compositions thereof | |
| CN104758358A (en) | Medicine composite used for eczema and preparation method thereof | |
| CN114053329B (en) | Application of broussonetia papyrifera polysaccharide in preparation of medicines or sunscreen cosmetics for preventing and treating ultraviolet injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240307 Address after: Room 1304, No. 152 Huangbian North Road, Helong Street, Baiyun District, Guangzhou City, Guangdong Province, 510000 Patentee after: Guangzhou Wanqian vermicelli Cosmetics Co.,Ltd. Country or region after: China Address before: 610041 Fifth Floor 501, B3 Floor, Tianfu Life Science and Technology Park, 88 South Road, Fengjiawan Industrial Park, Chengdu High-tech Zone, Sichuan Province Patentee before: CHENGDU SCISYN PHARMACEUTICAL CO.,LTD. Country or region before: China |